118 related articles for article (PubMed ID: 37916740)
21. Combined targeting of epidermal growth factor receptor and hedgehog signaling by gefitinib and cyclopamine cooperatively improves the cytotoxic effects of docetaxel on metastatic prostate cancer cells.
Mimeault M; Johansson SL; Vankatraman G; Moore E; Henichart JP; Depreux P; Lin MF; Batra SK
Mol Cancer Ther; 2007 Mar; 6(3):967-78. PubMed ID: 17363490
[TBL] [Abstract][Full Text] [Related]
22. NOTCH3 promotes docetaxel resistance of prostate cancer cells through regulating TUBB3 and MAPK signaling pathway.
Sun X; Zhang Y; Xin S; Jin L; Cao Q; Wang H; Wang K; Liu X; Tang C; Li W; Li Z; Wen X; Yang G; Guo C; Liu Z; Ye L
Cancer Sci; 2024 Feb; 115(2):412-426. PubMed ID: 38115797
[TBL] [Abstract][Full Text] [Related]
23. Docetaxel-resistant prostate cancer cells become sensitive to gemcitabine due to the upregulation of ABCB1.
Seo HK; Lee SJ; Kwon WA; Jeong KC
Prostate; 2020 May; 80(6):453-462. PubMed ID: 32134535
[TBL] [Abstract][Full Text] [Related]
24. Long noncoding RNA MALAT1 enhances the docetaxel resistance of prostate cancer cells via miR-145-5p-mediated regulation of AKAP12.
Xue D; Lu H; Xu HY; Zhou CX; He XZ
J Cell Mol Med; 2018 Jun; 22(6):3223-3237. PubMed ID: 29633510
[TBL] [Abstract][Full Text] [Related]
25. The stem cell inhibitor salinomycin decreases colony formation potential and tumor-initiating population in docetaxel-sensitive and docetaxel-resistant prostate cancer cells.
Gruber M; Handle F; Culig Z
Prostate; 2020 Feb; 80(3):267-273. PubMed ID: 31834633
[TBL] [Abstract][Full Text] [Related]
26. JMJD2A participates in cytoskeletal remodeling to regulate castration-resistant prostate cancer docetaxel resistance.
Cai X; Duan X; Tang T; Cui S; Wu T
BMC Cancer; 2023 May; 23(1):423. PubMed ID: 37165308
[TBL] [Abstract][Full Text] [Related]
27. FOXM1 mediates resistance to docetaxel in gastric cancer via up-regulating Stathmin.
Li X; Yao R; Yue L; Qiu W; Qi W; Liu S; Yao Y; Liang J
J Cell Mol Med; 2014 May; 18(5):811-23. PubMed ID: 24628949
[TBL] [Abstract][Full Text] [Related]
28. Identification of lipidomic profiles associated with drug-resistant prostate cancer cells.
Ingram LM; Finnerty MC; Mansoura M; Chou CW; Cummings BS
Lipids Health Dis; 2021 Feb; 20(1):15. PubMed ID: 33596934
[TBL] [Abstract][Full Text] [Related]
29. Interferon inducible antiviral MxA is inversely associated with prostate cancer and regulates cell cycle, invasion and Docetaxel induced apoptosis.
Brown SG; Knowell AE; Hunt A; Patel D; Bhosle S; Chaudhary J
Prostate; 2015 Feb; 75(3):266-79. PubMed ID: 25327819
[TBL] [Abstract][Full Text] [Related]
30. Histone deacetylase inhibitor potentiates anticancer effect of docetaxel via modulation of Bcl-2 family proteins and tubulin in hormone refractory prostate cancer cells.
Hwang JJ; Kim YS; Kim MJ; Kim DE; Jeong IG; Kim CS
J Urol; 2010 Dec; 184(6):2557-64. PubMed ID: 21030039
[TBL] [Abstract][Full Text] [Related]
31. A novel histone deacetylase inhibitor, CG200745, potentiates anticancer effect of docetaxel in prostate cancer via decreasing Mcl-1 and Bcl-XL.
Hwang JJ; Kim YS; Kim T; Kim MJ; Jeong IG; Lee JH; Choi J; Jang S; Ro S; Kim CS
Invest New Drugs; 2012 Aug; 30(4):1434-42. PubMed ID: 21773733
[TBL] [Abstract][Full Text] [Related]
32. MicroRNA-223-3p regulates cell chemo-sensitivity by targeting FOXO3 in prostatic cancer.
Feng Q; He P; Wang Y
Gene; 2018 Jun; 658():152-158. PubMed ID: 29518547
[TBL] [Abstract][Full Text] [Related]
33. Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profiling.
Zhao L; Lee BY; Brown DA; Molloy MP; Marx GM; Pavlakis N; Boyer MJ; Stockler MR; Kaplan W; Breit SN; Sutherland RL; Henshall SM; Horvath LG
Cancer Res; 2009 Oct; 69(19):7696-703. PubMed ID: 19773444
[TBL] [Abstract][Full Text] [Related]
34. Silencing of miR-193a-5p increases the chemosensitivity of prostate cancer cells to docetaxel.
Yang Z; Chen JS; Wen JK; Gao HT; Zheng B; Qu CB; Liu KL; Zhang ML; Gu JF; Li JD; Zhang YP; Li W; Wang XL; Zhang Y
J Exp Clin Cancer Res; 2017 Dec; 36(1):178. PubMed ID: 29216925
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of histone deacetylase 6 destabilizes ERK phosphorylation and suppresses cancer proliferation via modulation of the tubulin acetylation-GRP78 interaction.
Wattanathamsan O; Chantaravisoot N; Wongkongkathep P; Kungsukool S; Chetprayoon P; Chanvorachote P; Vinayanuwattikun C; Pongrakhananon V
J Biomed Sci; 2023 Jan; 30(1):4. PubMed ID: 36639650
[TBL] [Abstract][Full Text] [Related]
36. Temozolomide-resistant Glioblastoma Depends on HDAC6 Activity Through Regulation of DNA Mismatch Repair.
Kim GW; Lee DH; Yeon SK; Jeon YH; Yoo J; Lee SW; Kwon SH
Anticancer Res; 2019 Dec; 39(12):6731-6741. PubMed ID: 31810938
[TBL] [Abstract][Full Text] [Related]
37. Combination treatment with docetaxel and histone deacetylase inhibitors downregulates androgen receptor signaling in castration-resistant prostate cancer.
Park SE; Kim HG; Kim DE; Jung YJ; Kim Y; Jeong SY; Choi EK; Hwang JJ; Kim CS
Invest New Drugs; 2018 Apr; 36(2):195-205. PubMed ID: 29110173
[TBL] [Abstract][Full Text] [Related]
38. Protein Disulfide Isomerase 4 Drives Docetaxel Resistance in Prostate Cancer.
Qian S; Zhang S; Wu Y; Ding Y; ; Li X
Chemotherapy; 2020; 65(5-6):125-133. PubMed ID: 33238278
[TBL] [Abstract][Full Text] [Related]
39. miR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1.
Wang Y; Lieberman R; Pan J; Zhang Q; Du M; Zhang P; Nevalainen M; Kohli M; Shenoy NK; Meng H; You M; Wang L
Mol Cancer; 2016 Nov; 15(1):70. PubMed ID: 27832783
[TBL] [Abstract][Full Text] [Related]
40. PrLZ increases prostate cancer docetaxel resistance by inhibiting LKB1/AMPK-mediated autophagy.
Zeng J; Liu W; Fan YZ; He DL; Li L
Theranostics; 2018; 8(1):109-123. PubMed ID: 29290796
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]